AstraZeneca shares down after Pfizer walks away


A woman walks outside AstraZeneca headquarters in Macclesfield, northwest England. Analysts say now that the Pfizer bid has gone, AstraZeneca would need to deliver on its aggressive 2023 targets. - AFP

LONDON: Shares in AstraZeneca fell 2.3% after US drugmaker Pfizer said it would not make a formal bid to acquire its smaller British rival.

Pfizer’s decision – announced on Monday during a public holiday – had been widely expected after a rejection by AstraZeneca’s board of its final offer of £55 a share.

Save 30% OFF The Star Digital Access

Monthly Plan

RM 13.90/month

RM 9.73/month

Billed as RM 9.73 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 8.63/month

Billed as RM 103.60 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
Business , astrazaneca

Next In Business News

Reading the market signals
Urban harmony: Can stakeholders row together?
Breathing new life into forgotten spaces
FROM BANGSAR TO BEYOND
Asia to lead next AI wave
Luxury real estate trends in 2026
China’s gold rush continues
SC Estate Builder’s hotel acquisition under scrutiny
Department stores bet on experiences
Jakarta set to rise

Others Also Read